Article Figures & Data
Figures
- Figure 1.
Efficacy of vaccine with and without 4-1BB mAb to inhibit the development of lymphoma in Eμ-myc transgenic mice. A, Schematic of treatment schedule. B, Survival of Eμ-myc transgenic mice that received irradiated tumour cell vaccine or 4-1BB mAb, either alone or in combination. Shaded gray box, age at initiation of treatment. C, IFNγ production and CD69 expression on NK, NKT, and CD8+ T cells in the blood 24 hours after receiving vaccine. ND, not detected. D, Numbers of CD8+ T cells and proportion of CD8+ T cells expressing CD44 in the blood at 6.7 to 7 weeks after initiation of treatment. ns, not significant. Statistics: log-rank (Mantel–Cox) test (B), Mann–Whitney t test (C), one-way ANOVA with Holm–Sidak multiple comparison test (D). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Data shown are from a single experiment.
- Figure 2.
Generation of a protective antilymphoma memory response in long-term Eμ-myc survivors. A, Individual mouse tumor growth curves for GFP+ Eμ-myc 299 in Eμ-myc transgenic mice that were initially untreated, or had received either 4-1BB mAb or vaccine + 4-1BB mAb >25 weeks earlier. B, Mean GFP+ Eμ-myc 299 tumor burden ± SEM over time and at 14 days after Eμ-myc 299 tumor inoculation. ns, not significant. C, Representative dot plots of tumor burden (top); KLRG1 expression on activated CD8 T cells (bottom) 14 days after tumor inoculation. Statistics: one-way ANOVA with Dunn multiple comparison test (B). *, P < 0.05; ***, P < 0.001.
- Figure 3.
PD-1 blockade abrogated the protective antitumor effect induced by 4-1BB mAb. A, PD-1 expression on CD8+ T cells in untreated Eμ-myc transgenic mice or 20 weeks after 4-1BB mAb treatment. MFI, mean fluorescence intensity. B, Survival of Eμ-myc transgenic mice that received 4-1BB mAb or PD-1 mAb, either alone or in combination. Shaded gray box, age at initiation of treatment (RX). ns, not significant. C, Percent of CD8+ T cells in the blood that are CD44+ CD62L− (TEM) or CD44+ CD62L− (TCM) after 4-1BB mAb or PD-1 mAb, either alone or in combination. Lines, individual mice. Statistics: log-rank (Mantel–Cox) test (B). *, P < 0.05. Data compiled from sequential cohorts of treated mice.
- Figure 4.
PD-1 blockade abrogated the expansion of activated memory cells induced by 4-1BB mAb. A, Number of activated CD8+ CD44+ cells in the blood of Eμ-myc transgenic mice after vaccine, 4-1BB mAb, or PD-1 mAb either alone or in combination. Shaded gray box, two treatment cycles. B, Percent of CD8+ T cells that are KLRG1+ CD127− (SLEC) or KLRG1+ CD127+ (DPEC) after vaccine, 4-1BB mAb, or PD-1 mAb, either alone or in combination. ns, not significant. C, Representative dot plots of KLRG1 and CD127 expression on CD8+ T cells after vaccine, 41BB mAb, or PD-1 mAb, either alone or in combination. Statistics:one-way ANOVA with Dunnett multiple comparison test (B). *, P < 0.05; **, P < 0.01; ***, P < 0.001, ****, P < 0.0001.
Volume 5, Issue 3
